Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Hisamitsu Licenses for Percutaneous Pain Killer from Mundipharma
August 27, 2007
- R&D NEWS IN BRIEF
August 27, 2007
- Toho Pharm., Ohki, and Kokubu to Tie Up
August 27, 2007
- OPINION／Our Attitude Leads to Our Altitude
August 27, 2007
- Korosho Presents "Emergency Proposals" to Improve Business Practices
August 27, 2007
- Industry, Gov't, Academia to Jointly Develop New Medical Devices
August 27, 2007
- Discussion on Copyright on Literature Resumed
August 27, 2007
- MEDICAL DEVICE NEWS IN BRIEF
August 27, 2007
- BUSINESS NEWS IN BRIEF
August 27, 2007
- MOF Demands \220 Bil. Cut in Social Security Spending Again in FY2008
August 27, 2007
- Chuikyo to Show Road Map for Revisions of Medical Fees in April 2008
August 27, 2007
- SEMINAR
August 27, 2007
- Korosho Starts Studies for Mutual Acceptance of Clinical Data from Japan, Korea, China
August 27, 2007
- DSP to Independently Market Lurasidone in US
August 27, 2007
- MEDICAL DEVICE NEWS IN BRIEF
August 20, 2007
- JGPMA to Enhance Reliability of Generics: Mr Sawai
August 20, 2007
- Candidates Recommended by JMA, JPA Lose Seats in Upper House
August 20, 2007
- JMA Presents Strong Objection to the Use of Generics: Chuikyo
August 20, 2007
- LDP Must Review Its Medical Expenditure Curtailment Policy: JMA
August 20, 2007
- New NHI Pricing Systems Proposed by Industry Organizations
August 20, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…